Recently completed trial tests tolerability of CBD and glucosamine formulation in dogs

December 15, 2020
Sebastian Krawiec

Companion Sciences has announced the completion of a new trial testing tolerability and palatability of CBD and glucosamine chew in dogs with osteoarthritis.

Companion Sciences (New York City, NY) has announced the completion of a new trial conducted by The Ohio State University College of Veterinary Medicine’s Blue Buffalo Veterinary Clinical Trials Office (BBVCTO). In the tolerability and palatability trial, a group of osteoarthritic dogs was given a patent-pending chew from Companion Sciences containing CBD and glucosamine. The dogs, between the ages of 4.8 and 9.5, were physical examinations, as well as routine blood and urine analyses. Companion Sciences is a start-up investigating the ability of CBD to potentiate the bioavailability of a range of nutrients and other compounds to create a post-commodity future for CBD.

“We are encouraged by these tolerability and palatability results” said Golan Vaknin, CEO of Companion Science, in a press release. “A critical milestone, as part of our mission as an R&D company is to bring a new level of evidence-based validation to the ‘wild west’ that characterizes the CBD market. This study was an essential step in that journey; it follows on our baseline research, led by our Research Director Dr. Tami Bar and conducted by the prestigious Pharmacology Discovery Services in Taiwan. This study found that our formulation achieved high-levels of bio-absorption in a rat model, including penetration into the synovial fluid, the seat of joint inflammation.”

Following the tolerability and palatability study, Companion Sciences intends to launch a safety and efficacy trial with dogs suffering from osteoarthritis.